| |
| |
|
| Insider
Information: |
Zakrzewski Joseph S |
| Relationship: |
|
| City: |
Bedford |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
647,942 |
|
|
Indirect Shares
|
554,931 |
|
|
| Direct
Value |
$12,363,584 |
|
|
|
Indirect Value
|
$1,391,776 |
|
|
| Total
Shares |
1,202,873 |
|
|
| Total
Value |
$13,755,359 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
21
|
1
|
|
Stock
price went up :
|
2
|
0
|
| Stock
price went down : |
19
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
 -40.0%
|
-88.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Insulet Corp |
PODD |
Director |
2017-05-17 |
30,558 |
2008-11-11 |
0 |
Premium* |
|
|
Amarin Corp Plc |
AMRN |
|
2021-12-15 |
196,547 |
|
0 |
Premium* |
|
|
Liposcience Inc |
LPDX |
Director |
2014-11-20 |
0 |
2014-06-11 |
0 |
Premium* |
|
|
Acceleron Pharma Inc |
XLRN |
Director |
2021-04-01 |
34,499 |
2016-12-30 |
0 |
Premium* |
|
|
Sangamo Biosciences Inc |
SGMO |
Director |
2022-02-25 |
60,700 |
2018-06-11 |
0 |
Premium* |
|
|
Cyteir Therapeutics, Inc. |
CYT |
Director |
2024-02-06 |
227,439 |
2024-02-06 |
149,051 |
Premium* |
|
|
An2 Therapeutics Ord Shs |
ANTX |
|
2024-01-18 |
98,199 |
2024-01-18 |
405,880 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2024-02-06 |
4 |
OE |
$1.69 |
$23,914 |
D/D |
14,150 |
227,439 |
0 |
- |
|
| ANTX |
An2 Therapeutics Ord Shs |
|
– • – |
2024-01-18 |
4 |
S |
$19.11 |
$1,911,410 |
I/I |
(100,000) |
405,880 |
0 |
% |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2022-12-07 |
4 |
B |
$1.30 |
$27,563 |
D/D |
21,202 |
154,618 |
2.39 |
% |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2022-05-12 |
4 |
B |
$1.61 |
$1,196 |
D/D |
743 |
133,416 |
2.31 |
% |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2022-05-11 |
4 |
B |
$1.70 |
$1,700 |
D/D |
1,000 |
132,673 |
2.31 |
% |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2022-05-10 |
4 |
B |
$1.89 |
$93,377 |
D/D |
49,406 |
131,673 |
2.39 |
% |
|
| ANTX |
An2 Therapeutics Ord Shs |
Director |
– • – |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
98,199 |
98,199 |
0 |
- |
|
| ANTX |
An2 Therapeutics Ord Shs |
Director |
– • – |
2022-03-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
505,880 |
|
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2022-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
60,700 |
0 |
- |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2021-12-28 |
4 |
B |
$9.85 |
$5,920 |
D/D |
601 |
82,267 |
2.39 |
% |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2021-12-27 |
4 |
B |
$9.97 |
$3,002 |
D/D |
299 |
81,666 |
2.31 |
% |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2021-12-23 |
4 |
B |
$9.87 |
$1,974 |
D/D |
200 |
81,367 |
2.31 |
% |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2021-12-17 |
4 |
B |
$9.88 |
$1,976 |
D/D |
200 |
81,167 |
2.31 |
% |
|
| AMRN |
Amarin Corp Plc |
|
– • – |
2021-12-15 |
4 |
B |
$3.16 |
$6,310 |
D/D |
2,000 |
196,547 |
0.01 |
% |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2021-12-15 |
4 |
B |
$10.47 |
$39,844 |
D/D |
3,700 |
80,967 |
2.39 |
% |
|
| AMRN |
Amarin Corp Plc |
|
– • – |
2021-12-14 |
4 |
B |
$3.27 |
$32,689 |
D/D |
10,000 |
194,547 |
0.01 |
% |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2021-06-22 |
4 |
A |
$0.00 |
$0 |
I/I |
58,671 |
58,671 |
0 |
- |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2021-06-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
149,051 |
|
- |
|
| CYT |
Cyteir Therapeutics, Inc. |
Director |
– • – |
2021-06-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
77,267 |
|
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2021-04-01 |
4 |
AS |
$132.61 |
$1,346,382 |
D/D |
(10,000) |
34,499 |
0 |
% |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2021-04-01 |
4 |
OE |
$24.11 |
$241,100 |
D/D |
10,000 |
44,499 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,200 |
48,200 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,622 |
34,499 |
0 |
- |
|
| AMRN |
Amarin Corp Plc |
|
– • – |
2020-10-21 |
4 |
OE |
$3.40 |
$340,000 |
D/D |
100,000 |
184,547 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
Director |
– • – |
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
32,500 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
